Flavopiridol Pharmacogenetics: Clinical and Functional Evidence for the Role of SLCO1B1/OATP1B1 in Flavopiridol Disposition

BACKGROUND: Flavopiridol is a cyclin-dependent kinase inhibitor in phase II clinical development for treatment of various forms of cancer. When administered with a pharmacokinetically (PK)-directed dosing schedule, flavopiridol exhibited striking activity in patients with refractory chronic lymphocy...

Descripción completa

Detalles Bibliográficos
Autores principales: Ni, Wenjun, Ji, Jia, Dai, Zunyan, Papp, Audrey, Johnson, Amy J., Ahn, Sunjoo, Farley, Katherine L., Lin, Thomas S., Dalton, James T., Li, Xiaobai, Jarjoura, David, Byrd, John C., Sadee, Wolfgang, Grever, Michael R., Phelps, Mitch A.
Formato: Texto
Lenguaje:English
Publicado: Public Library of Science 2010
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2967470/
https://www.ncbi.nlm.nih.gov/pubmed/21072184
http://dx.doi.org/10.1371/journal.pone.0013792

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2967470/
https://www.ncbi.nlm.nih.gov/pubmed/21072184
http://dx.doi.org/10.1371/journal.pone.0013792

Ejemplares similares